A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Paul Johnson
Advertisement
Paul Johnson is scientist at Pfizer Global Research and Development Global Biologics, Bioprocess R&D
Articles by Paul Johnson
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
2
FDA Reportedly Pauses National Priority Voucher Pilot and Pauses CRL Publication
3
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
4
FDA Clears IND for Biolojic’s BD200, the First AI-Designed Multibody ADC to Enter Clinical Trials
5